ArticleJournal of neuro-oncology2026
Improved tumor control with adjuvant radiotherapy in patients with central neurocytoma: a multicenter study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience.Journal of neuro-oncology · 2026Article
- Central neurocytomas: Decision-making process of postoperative treatment. Lesson learned.Neurosurgical review · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThe benefit of external beam radiotherapy (EBRT) over Gamma Knife surgery (GKS) for central neurocytoma (CN) remains unclear. The aim of this retrospective, multicenter study was to investigate the role of adjuvant radiotherapy (ART) after surgical removal of CN and compare the outcomes of these modalities.
methodsWe included 128 patients with CN who underwent surgery during 2000–2020. Patients were categorized according to the extent of resection, Ki-67 labeling index, and ART modality. Progression-free survival (PFS) was assessed using Kaplan–Meier analysis and Cox proportional-hazards modeling.
resultsThe median tumor size and follow-up duration were 5 cm and 66 months, respectively. ART was independently associated with an improved PFS (p = 0.005). Five-year PFS rates were higher among patients who received EBRT (n = 20, 95.0%), compared to GKS (n = 21, 78.3%, p = 0.061) and no radiotherapy (n = 87, 71.4%, p = 0.035). In the gross total resection and Ki-67 index > 2% subgroups, the PFS was higher in the EBRT group than that in the rest (p = 0.026). In patients with a Ki-67 index ≤ 2%, no PFS difference was observed between the ART and no-radiotherapy subgroups (p = 0.952). Among patients receiving ART, EBRT resulted in a longer PFS than GKS (p = 0.029 upon multivariable analysis).
conclusionsART may improve tumor control in patients with CN. Even in patients who undergo total resection, ART may be beneficial in the Ki-67 index > 2% subgroup. EBRT may result in superior PFS to GKS among patients with surgically resected CN.
Indexed as
Identifiers
41872623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.